TacticScaleWhat InnoCare Pharma Does & How It Makes Money (9969.HK)
Updated October 2026 · reflects InnoCare Pharma's latest reported financials
Chinese biotech developing cancer and autoimmune disease drugs. It earns revenue mainly by selling its approved drugs, led by orelabrutinib, and may also receive collaboration and licensing income from partners such as Eli Lilly.
How InnoCare Pharma makes money
It earns revenue mainly by selling its approved drugs, led by orelabrutinib, and may also receive collaboration and licensing income from partners such as Eli Lilly.
What InnoCare Pharma does
InnoCare Pharma is a Beijing-based biopharmaceutical company founded in 2015. It discovers, develops and commercializes drugs for cancer and autoimmune diseases in China. Its flagship drug, orelabrutinib, is a BTK inhibitor used for relapsed or hard-to-treat blood cancers, including chronic lymphocytic leukemia, mantle cell lymphoma, Waldenstrom's macroglobulinemia and marginal zone lymphoma. It is also being studied for lupus, immune thrombocytopenia, multiple sclerosis and neuromyelitis optica spectrum disorder. Beyond orelabrutinib, the pipeline includes zurletrectinib (ICP-723) for NTRK fusion-positive cancers, ICP-248 for chronic lymphocytic leukemia, ICP-189 for non-small cell lung cancer, ICP-332 for atopic dermatitis, ICP-488 for psoriasis, and biologics such as ICP-B02 and ICP-B05. The company also has a research collaboration and license agreement with Eli Lilly.
Products & services
- Orelabrutinib (BTK inhibitor)
- Zurletrectinib (ICP-723)
- ICP-248
- ICP-332
- ICP-488
- ICP-B02
What is InnoCare Pharma worth?
A reliable owner-earnings fair value isn't available for this company yet — we'd rather say so than print a number we don't trust.
We show a fair value only when the method is trustworthy. See InnoCare Pharma on TacticScale →
Related companies
InventisBio (688382.SS) · Incyte (INCY) · BeOne Medicines (688235.SS)